Other areas

XG-4xx, an inhibitor of the anti-apoptotic proteins Bcl-XL and Mcl-1, has shown promise in preliminary studies in tumor models and is being investigated for use in the treatment of leucemias, lymphomas, and lung and skin cancers.

XG-3xx is a widely used antineoplastic coupled to a proprietary carrier sequence that shows activity in a variety of transformed cell types.

XG-5xx is an inhibitor of HIV protease dimer formation that shows potency equivalent to saquinavir in viral replication assays.

Cochlear injuries such as exposure to excessive noise, disturbances of the blood supply, viral or bacterial infections, and exposure to certain ototoxic substances lead to inflammatory responses and apoptosis of hair cells and neurons that may result in irreversible hearing loss. Administration of XG-102 (AM-111) has been shown in animal models to effectively protect cochlear hair cells and neurons following such injuries and to preserve hearing.

XG-102 (AM-111) is in clinical development in acute sensorineural hearing loss with development partner Auris Medical. Initial evidence for safety, local tolerance and potential clinical benefit was obtained in a successfully completed Phase I/II trial on 11 patients with acute hearing loss who received a single dose transtympanic injection. XG-102 (AM-111) is currently in a multicentre Phase IIb trial with 200 patients.